Neoleukin Therapeutics, Inc. has announced a merger plan with Neurogene Inc., where a wholly owned subsidiary of Neoleukin, called 'Merger Sub', will merge with Neurogene making the latter a wholly owned subsidiary of Neoleukin, intending to qualify as a tax-free reorganization. Post-merger, Neurogene stockholders will own approximately 84% of the combined company and Neoleukin approximately 16%. The completion of the merger is subject to conditions including approval by Neurogene stockholders, Neoleukin net cash equalling a minimum of $60 million and Neurogene receiving a minimum of $75 million cash proceeds.